Abstract
The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Anti-Infective Agents
Title:The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery
Volume: 11 Issue: 2
Author(s): Hsiang-Kuang Tseng, Sheng-He Huang, Gregory Shackleford and Ambrose Jong
Affiliation:
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Abstract: The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Export Options
About this article
Cite this article as:
Tseng Hsiang-Kuang, Huang Sheng-He, Shackleford Gregory and Jong Ambrose, The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020005
DOI https://dx.doi.org/10.2174/2211352511311020005 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug
Current Molecular Pharmacology Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry Characterization and antiherpetic activity of native and chemically sulfated polysaccharide from <i>Adenanthera pavonina</i>
Current Pharmaceutical Biotechnology Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Structure and Functions of Bacterial Outer Membrane Protein A, A Potential Therapeutic Target for Bacterial Infection
Current Topics in Medicinal Chemistry Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety